Meeting an Unmet Need in the Nonmetastatic Castration Resistant Prostate Cancer Patient Population - Maha Hussain
March 19, 2018
Alicia Morgans and Maha Hussain discuss the Evaluating the Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (PROSPER) phase III randomized double-blind controlled trial, in the nonmetastatic castration-resistant prostate cancer (nmCRPC) patient population which was first presented at the 2018 ASCO GU meeting.
The purpose of this study is to assess the safety and efficacy of enzalutamide (ENZA) in patients with nmCRPC (M0 prostate cancer). At the time of the study, there was not any approved FDA agents in this patient population. PROSPER specifically looked at better personalization of care by selecting men who are destined to develop metastatic disease sooner rather than later by looking at the PSA doubling time of 10 months or less based on prior trials that demonstrated that the cut off seemed to be at least predictive of developing metastases.
Maha Hussain, MD, FACP, FASCO, is the Genevieve Teuton Professor of Medicine in the Division of Hematology Oncology, Department of Medicine, and the Deputy Director at the Robert H. Lurie Comprehensive Cancer Center of the Northwestern University Feinberg School of Medicine.
Alicia Morgans, MD, MPH
More Related Content:
Watch: Changing the Standard of Care in the M0 CRPC Patient: PROSPER - A Conversation with Cora Sternberg
A Multinational, Phase 3, Randomized, Double Blind, Placebo Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration Resistant Prostate Cancer
PROSPER Trial Results of Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer
First Presentation - PROSPER: Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC)